A new study has found that patients with type 2 diabetes using GLP-1 receptor agonist drugs, such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), face a higher risk of clinically recorded hair loss compared to those using other common diabetes medications.